{"id":"shr-a2102-and-adebrelimab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL4297828","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking this interaction, SHR-A2102 and Adebrelimab enhance T-cell activation and proliferation, leading to anti-tumor immune responses. This mechanism is similar to other PD-1 inhibitors, such as pembrolizumab and nivolumab.","oneSentence":"SHR-A2102 and Adebrelimab are anti-PD-1 monoclonal antibodies that inhibit the PD-1/PD-L1 interaction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:30.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07393542","phase":"PHASE3","title":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-02-12","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":462},{"nctId":"NCT06547736","phase":"PHASE2","title":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-14","conditions":"Pancreatic Cancer","enrollment":160},{"nctId":"NCT06512051","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-07-30","conditions":"Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":248},{"nctId":"NCT07059221","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-07-11","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT07041437","phase":"PHASE2","title":"Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-30","conditions":"Advanced Breast Cancer","enrollment":48},{"nctId":"NCT06474468","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-06-20","conditions":"Advanced or Metastatic Esophageal Cancer","enrollment":148},{"nctId":"NCT06417554","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-05-13","conditions":"Advanced Solid Tumors","enrollment":80},{"nctId":"NCT06639347","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-04","conditions":"Advanced Urothelial Carcinoma","enrollment":90},{"nctId":"NCT06589778","phase":"PHASE1, PHASE2","title":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-09-27","conditions":"Non-Small Cell Lung Cancer","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-A2102 and Adebrelimab","genericName":"SHR-A2102 and Adebrelimab","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A2102 is being studied in combination with other antitumor drugs for the treatment of Advanced Breast Cancer. Adebrelimab is also being studied in various conditions, including Advanced Solid Tumors, Locally Advanced or Metastatic Urothelial Carcinoma, and Advanced or Metastatic Non-small Cell Lung Cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}